Arcutis Announces Arcutis Cares™ Patient Assistance Program (PAP) For Financially Qualified Uninsured and Underinsured Patients

2 years ago

Arcutis Cares provides ZORYVE™ (roflumilast) cream 0.3% at no cost for financially eligible individuals who are uninsured or have Medicaid…

Kronos Bio Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Lanraplenib in Combination with Gilteritinib in Acute Myeloid Leukemia

2 years ago

SAN MATEO, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the…

Novo Nordisk successfully completes phase 2 trial with CagriSema in people with type 2 diabetes

2 years ago

Bagsværd, Denmark, 22 August 2022 – Novo Nordisk today announced headline results from a phase 2 clinical trial with CagriSema,…

Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets

2 years ago

World first study utilizing Somalogic SomaScan® assay# to assess up to 7,000 plasma proteins in Long COVID-19 patients has elucidated…

VitalHub Announces Licensing Agreement of Pre-Op Solutions, Synopsis Home and Synopsis iQ, to Bolton NHS Foundation Trust

2 years ago

TORONTO, Aug. 22, 2022 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI | OTCQX: VHIBF) is pleased…

Assure Holdings Corp. Prices $6.2 Million Underwritten Public Offering of Common Stock

2 years ago

DENVER, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (NASDAQ: IONM) ("Assure Holdings" or the "Company"), a provider of…

Aurora Spine Corporation Schedules Release of Second Quarter Fiscal Year 2022 Financial Results and Conference Call

2 years ago

CARLSBAD, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF),…

Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease

2 years ago

CALGARY, Alberta, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled…

Fennec Pharmaceuticals Closes First $5 Million Investment From Petrichor

2 years ago

~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to…

Bright Peak Therapeutics Announces the Appointment of Cancer Immunotherapy Leader Jon Wigginton, M.D., as President of Research and Development

2 years ago

SAN DIEGO and BASEL, Switzerland, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a biotechnology company developing next-generation precision…